Abstract: The role of the polyomavirus BK (BKV) large tumor antigen (L-Tag) as target of immune response in patients with prostate cancer (PCa) has not been investigated so far. In this study we have comparatively analyzed humoral and cellular L-Tag specific responsiveness in age matched patients bearing PCa or benign prostatic hyperplasia (BPH), expressing or not expressing BKV L-Tag specific sequences in their tissue specimens, and in non-age-matched healthy individuals. Furthermore, results from patients with PCa were correlated to 5-year follow-up clinical data focusing on evidence of biochemical recurrence (BR) following surgery (PSA0.2ng/ml).In peripheral blood mononuclear cells (PBMC) from patients with PCa with evidence of BR and BKV L-Tag positive tumors, stimulation with peptides derived from BKV L-Tag, but not those derived from Epstein Barr virus, influenza virus or Cytomegalovirus, induced a peculiar cytokine gene expression profile, characterized by high expression of IL-10 and TGF-1 and a low expression of IFN-genes. This pattern was confirmed by protein secretion data and correlated with high levels of anti BKV L-Tag IgG. Furthermore, in PBMC from these PCa bearing patients, L-Tag derived peptides significantly expanded an IL-10-secreting CD4(+)CD25(+(high))CD127(-(dim))FoxP3(+) T cell population with an effector memory phenotype (CD103(+)) capable of inhibiting proliferation of autologous anti-CD3/CD28 triggered CD4(+)CD25(-) T cells. Collectively, our findings indicate that potentially tolerogenic features of L-Tag specific immune response are significantly associated with tumor progression in patients with BKV+ PCa. 
Prostate cancer (PCa) represents the first leading cause of cancer morbidity and the third 2 of cancer death in men in developed countries with a worldwide incidence rate of 14% of total 3 newly diagnosed malignancies and a worldwide total cancer mortality rate of 6% (29) . A 4 contemporary model of PCa induction and progression should include the analysis of the 5 contribution of inflammation to the development of preneoplastic or neoplastic lesions (24). 6 Indeed, proliferative inflammatory atrophy (PIA) of the prostate has recently gained importance 7 as potential precursor of prostatic intraepithelial neoplasia (PIN) and overt PCa (15), (14) . This 8 owes particularly to the prevalence of PIA in the peripheral zone of the organ, where histological 9 transition between PIA and PIN usually occurs (42). 10 The low rate of mutations detected in tumor suppressor genes pRB1 and p53 in primary PCa 11 cells (16) has suggested a possible role of inflammatory agents ubiquitous in the urinary tract 12 with unique oncogenic functions, that is of sequestering wild-type products of tumor suppressor 13 genes. Polyomaviruses' main regulatory proteins large tumor antigens (L-Tag) interfere with wt-14 p53 binding to cellular DNA during virus infection (4), thereby impairing p53 control on cell 15 growth activity and possibly leading to oncogenic transformation in non-permissive cells (6) . As 16 such, the human urotheliotrophic polyomavirus BK (BKV) has been suggested to prominently 17 associate with the development of cancer (26, 27), and, in particular, of urinary tract 18 malignancies (3, 12, 54). 19
There is a continuing debate on BKV expression in overt cancers (1, 5). However, the 20 possibility of "hit and run" carcinogenic mechanisms induced by BKV cannot be excluded (13) . 21
Genetically rearranged BKV variants (45), (22), presumably difficult to detect by commonly used 22 assays, might exist in the urinary tract and be responsible for neoplastic transformation in prostate 23 β1) (Applied Biosystems, Rotkreuz, Switzerland). β-actin was used as endogenous reference 1 gene and normalized data were analyzed by the 2 -∆∆Ct method (34)
Cell cultures 4
Monocytes (CD14 + ) sorted from PBMC by magnetic beads (Miltenyi Biotech) were 5 cultured from 5 to 7 days in RPMI complete medium supplemented with 10% FCS ( GIBCO 6 Paisley, Scotland), 0.004% β-mercaptoethanol, rhIL-4 (1000 U/ml) and rhGM-CSF (50 ng/ml) to 7 generate immature DCs (iDCs). To induce maturation, iDCs were overnight exposed to 1 μg/ml 8 LPS (Abortus Aequi, Sigma-Aldrich, St. Louis, MO, USA). CD4 + T cells positively sorted from 9 PBMC by magnetic beads were cultured in complete medium with 5% human serum in 24 flat -10 bottom well plates at a 1x10 6 cells/ml concentration in the presence of autologous irradiated 11 mature DC (mDCs), previously pulsed for 2 hours with peptide pools (10 µg/ml), either for 12 priming (day 0) or re-stimulation (day 7). Recombinant human IL-2 (rhIL-2; Hoffmann-LaRoche, 13
Basel, Switzerland) was added to cultures at 1ng/ml, 1ng/ml and 5ng/ml, on days 3, 7 and 10, 14 respectively. 15
Regulatory T cell cultures were established by ex vivo magnetic sorting of 16
CD4
+ C25 + CD127 -/dim subset, as previously described (48). Cells were subsequently stimulated 17 with L-Tag peptide-pool (5µg/ml) or control peptides, including HCMVpp65 340-355 and HIV 18 peptide-pool, in the presence of 10 µg/ml anti-CD28 (BD Bioscience, Allschwil, Switzerland) 19 and 5 ng/ml of rIL-2. Cultures were similarly restimulated on day 7. IL-10-secreting Treg were 20 sorted on day 14 by cytokine secretion assay (Miltenyi Biotec, Germany). For suppression 21 assays, CD4 + CD25 +(high) CD127
-(dim)
, IL-10-secreting T cells were cultured in the upper chamber 22 of 24-transwell plates (BD Bioscience, Allschwil, Switzerland) with a double amount 23 (ratio=0.5:1) of autologous CD4 + CD25 -T cells, stimulated with 1mg/ml of anti CD3/CD28 (BD 1 Bioscience, Allschwil, Switzerland) seeded in the lower chamber, and cultured for 8 days. 2
+ CD25 -T cells proliferation was measured using Cell Proliferation Reagent WST-1 (Roche 3 Applied Science, Rotkreutz, Switzerland) according to manufacturer's instructions and 4 absorbance was read at 450nm with an ELISA plate reader. 5 6 Regulatory T cell quantification by flow cytometry 7
+ T cells stimulated by peptide-pools, as described above, were stained with anti-CD4 8 FITC and anti-CD25 APC antibodies (BD Biosciences, Allschwil, Switzerland). Anti FoxP3 PE 9 antibodies and FoxP3 Fix/Perm buffer were used for intracellular staining according to 10 manufacturer's protocol (eBioscience, Vienna, Austria). Separation into CD25 bright (CD25 Vienna, Austria), and referred to a standard curve for quantification. 23
Statistical analysis 1
Statistical analysis was performed with Graph Pad Prism (version 5.1) and SAS/STAT 2 (version 9.1). Data were reported as mean ± standard deviations (SD) or mean ± standard errors 3 (SE), median and ranges where appropriate. Distributions of categorical markers were analyzed 4 by both χ 2 and Fisher's exact tests. Groups following normal distribution (Shapiro-Wilk test) 5
were compared with t-tests (either Pooled or Cochran method) and F-test was used to calculate 6 variance among groups of samples. If non-normal distribution was indicated, nonparametric tests 7 such as Mann-Whitney U tests and Spearman's ρ correlation analyses were used. P values <0.05 8 (CI 95%) were considered statistically significant. 9
10

RESULTS
1
Clinical profiles of patients 2
The average age of patients enrolled in the study (n=110) was 64±7.7 years (range 49-90) for 3 PCa (n=60) and 67±7.4 years (range 48-81) for age-matched BPH (n=50), respectively. 4
Out of 60 PCa patients, 1 was diagnosed with clinical stage pT1b, 10 with pT2a, 2 with pT2b, 5 the majority (n=30; 51%) with clinical stage pT2c, 4 with pT3a and 3 with pT3b. Ten (17%) 6 patients had tumors whose stage at diagnosis could not be assessed. Average serum prostate 7 specific antigen (PSA) value was 17.4±36.2 ng/ml (median: 6.7 ng/ml, range: 1.6-206 ng/ml) in 8
PCa patients before surgery (n=50, 83%) and 5.6±5.7 ng/ml (median: 3.9 ng/ml, range: 0.4-26 9 ng/ml) in BPH patients (n=36, 72%). Gleason Score (GS) of tumor specimens (n=55, 92%) 10 ranged from 5 to 9 according to immunohistochemical analysis (Table 1) . 11 12 L-Tag DNA detection in tissue specimens and BKV specific humoral response 13 Presence of polyomavirus BK was analyzed by BKV L-Tag DNA detection in surgically 14 excised PCa (n=43/60, 72%) and BPH (n=38/50, 76%) specimens. Positive samples (hereafter 15 referred to as BKV+) were identified among both PCa (mean=451.4 copies/10 5 cells; n=18/43, 16 42%) and BPH (mean=391.5 copies/10 5 cells; n=12/38, 32%) with no significant quantitative 17 differences among groups of patients (p=0.72) (Figure 1a) . No significant association (χ 2 ) with 18 cancer (p=0.18) or Gleason Score (GS+ ≥7; p=0.82) was observed. However, high PSA levels 19 (PSA ≥4ng/ml) were more frequently detectable in sera from patients with BKV+ PCa (p<0.05). 20
Humoral response against BKV VP1-and L-Tag was analyzed in sera from patients with PCa 21 and BPH. Upon sample stratification based on BKV L-Tag DNA tissue testing, we noted that 22 levels of L-Tag specific IgG (OD) were significantly higher in patients bearing BKV+ than BKV-23 PCa (p=0.01), while they were similarly low in patients with BKV+ or BKV-BPH. In contrast, 1 anti VP1 IgG levels were similar in patients with PCa or BPH, irrespective of their BKV 2 molecular status (Figure 1b) expression ratio was significantly (p=0.04) higher in BKV specific IgG+ patients bearing BKV+ 22
PCa (n=17) than in BKV specific IgG+ patients with BKV+ BPH (n=6) (Figure 3c) . 23
Comparative analysis of L-Tag induced cytokine gene expression in patients bearing BKV+ 1
PCa with or without evidence of biochemical recurrence (BR). 2
The results obtained in the first part of our study suggested that BKV specific immune 3 response is characterized by specific features, particularly in patients bearing BKV+ PCa, as 4 compared to patients with BPH, let alone healthy donors. These data raised the obvious issue of 5 the association of this response pattern with PCa clinical course. 6
Therefore, considering their peculiar clinical condition, we analyzed in detail BKV L- Tag  7 peptide-induced cytokine gene expression in PBMC from patients bearing BKV+ cancers with 8 biochemical evidence of recurrence (BR+). BR was observed in 9/48 (19%) patients with PCa 9 with complete follow-up, after 6 weeks (n=6), 24 weeks (n=1), 48 weeks (n=1) and 96 weeks 10 (n=1). Two patients were excluded from the study because BKV molecular testing on tissue 11 lesions was not available (nt) ( Table 2) in PBMC from these patients, both ex vivo and following L-Tag peptide-pool-specific 20 stimulation. In particular, to adequately control our study, we focused on cells from L-Tag 21 specific IgG+ patients bearing BKV+ PCa with or without BR (n=7 and n= 8, respectively) and 22 from L-Tag specific IgG+ patients bearing BKV+ BPH (n=7) ( Table 2) . with PCa and found to correlate with metastatic behavior (55). 21 We previously showed that indoleamine-2, 3-deoxygenase (IDO) gene is frequently 22 expressed to high extents in PCa (19). The specific gene product plays a key role in tryptophan 23 metabolism and its enhanced activities might result in both the depletion of an amino acid 1 essential for lymphocyte metabolism and in the generation of toxic metabolites (53) . In addition, 2 arginase production by macrophages infiltrating prostatic tissues has been shown to favor the 3 induction of anergy in resident lymphocytes (8). Therefore, in patients bearing a BKV+ PCa, 4 presentation of L-Tag to T cells might occur in conditions likely favoring the generation of 5 immune responses characterized by a high IL-10/IFN-γ gene expression ratio. 6 Most obviously, our data do not allow the postulation of any causal relationship between 7 features of L-Tag specific immune responses, BKV infection and cancer. Nevertheless, they 8 suggest the existence of a complex interaction of potential clinical relevance. 9
Our study has a major limitation. Indeed, although it capitalizes on the analysis of specific 10 immune responses in a substantial number of patients, the number of informative cases, e.g. 11 patients bearing BKV+ lesions with or without BR, is relatively modest. Therefore, additional 12 investigations confirming these results in a larger number of cases are obviously warranted. PCa tested, co-cultured as described above. 9 
